Literature DB >> 2977623

NK cell activity and monocyte dysfunctions in a patient with common variable hypogammaglobulinemia.

M Clerici1, M L Villa, M Mantovani, C Rugarli.   

Abstract

A 57-year-old man with a history of recurrent infections from the age of 50 was hospitalized with a diagnosis of common variable hypogammaglobulinemia (CVH). Immunological studies revealed a severe reduction of circulating immunoglobulins of all classes. Immunophenotyping of peripheral blood mononuclear cells (PBMC) with monoclonal antibodies, revealed normal values of total B and T cells with CD4/CD8 ratio sharply reduced (0.35) as compared to normal (1.6) because of an increase of CD8 and a decrease of CD4 cells. The surface expression of IL-2 receptor was normal. Natural cytotoxic and phagocytic system presented several abnormalities: a deep impairment of NK activity was found in spite of a normal number of NK cells, as ascertained by Leu 19 and B73.1 monoclonal antibodies. The defective NK activity was not restored by interferon alfa, but was normalized by recombinant IL-2. Phagocytic function, as defined by zymosan-stimulated O2- production was almost absent. The involvement of natural cytotoxic and phagocytic systems in CVH has been rarely reported; the possible causative role of a chronic viral infection (Epstein-Barr virus?) is discussed, on the base of anamnesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2977623

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  2 in total

1.  Raised serum neopterin levels in patients with primary hypogammaglobulinaemia; correlation to other immunological parameters and to clinical and histological features.

Authors:  P Aukrust; S S Frøland; F Müller
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  Reduced natural killer cell activity and IL-2 production in malnourished cancer patients.

Authors:  M L Villa; E Ferrario; E Bergamasco; F Bozzetti; L Cozzaglio; E Clerici
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.